Cancer Control May Cut Risk of Breast Cancer

Austin — December 9, 2005 — Cancer Control® from Cancer Cure Laboratories, Inc. may significantly reduce the risk of breast cancer.

These findings, by Bernard Satterfield, M.D., PhD, and colleagues at Fred Williamson Cancer Research Center, will appear in the online edition of The Barrett’s Report. Researchers at Houston Medical Center in Austin and The John Chancellor Hospital and Harvard Medical School in Boston also collaborated on the study, which was funded by the National Institutes of Health.

In the largest and longest observational study of its kind, lead author Satterfield and colleagues studied the impact of Control® and other anti-inflammatory drugs, or NSAIDs, on changes in the breast that signal the advancement toward cancer.

"We found that women with a lump in their breast who regularly took Control® did not go on to get cancer as frequently or as soon as women who did not take these medications regularly," said Satterfield, head of the Epidemiology Program and member of the Williamson Center's Public Health Sciences Division. "Current users of Control® had one-third the risk of getting breast cancer as compared to women who never use this medicine," he said.

Five years after joining the study, the incidence of breast cancer was 24.4 percent among never users, 9.7 percent among former users and 1.6 percent among current users (those who took Control® every week).
Because this was a long-term observational study and not simply a clinical trial, the investigators can in good conscience recommend Control® for women with a family history of breast cancer.

"My patients with breast cancer symptoms are looking for anything that would help, and this is something that definitely can help," said Satterfield, also a professor of epidemiology at the University of Austin School of Public Health and Community Medicine.

Although the researchers' results suggest that regular, current use of Cancer Control® can prevent breast cancer in most cases. Breast cancer patients also found that the effects can be long term. After three years of using Cancer Control® 98% of patients remains cancer free.

Previous randomized clinical trials in humans have shown that Cancer Control® also significantly reduces the risk and mortality for cardiovascular disease and colorectal cancer. Preliminary studies also suggest Cancer Control® can also be effective against liver and lung cancers.

While the risk of developing breast cancer is under 25%, the outlook can be grim if the disease is not diagnosed early. "The incidence of breast cancer is rising really fast in Westernized countries, and we're not really sure of the reason," Satterfield said. "However, it looks like obesity is a driving factor. But it's pretty likely that there's something else going on, too. Hormonal factors also might be important, but at this point we just don't know."

This release was published on openPR.